- Home
- FMST vs CMMB Comparison
FMST vs CMMB Comparison
Compare FMST & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FMST | CMMB |
|---|---|---|
| Founded | 2005 | 2004 |
| Country | Canada | Israel |
| Employees | N/A | 16 |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.9M | 9.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | FMST | CMMB |
|---|---|---|
| Price | $2.34 | $1.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $26.50 |
| AVG Volume (30 Days) | ★ 327.3K | 61.8K |
| Earning Date | 02-12-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.55 | $1.42 |
| 52 Week High | $5.74 | $8.25 |
Technical Indicators
Market Signals| Indicator | FMST | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 50.99 | 39.38 |
| Support Level | $2.21 | $1.44 |
| Resistance Level | $2.55 | $1.66 |
| Average True Range (ATR) | 0.21 | 0.13 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 67.07 | 18.75 |
Price Performance
Historical ComparisonAbout FMST Foremost Lithium Resource & Technology Ltd.
Foremost Clean Energy Ltd is an emerging North American uranium and lithium exploration company. Its uranium portfolio consists of projects at different stages of exploration from grassroots, to those with historical exploration and drill-ready targets. It also maintains a secondary portfolio of lithium projects at different stages of development spanning 50,000-plus acres across Manitoba and Quebec. Geographically it covers Canada and United states.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.